Claritin (loratadine) is considered one of the preferred antihistamines for breastfeeding mothers. Only tiny amounts pass into breast milk, and at standard doses, it is not expected to cause adverse effects in breastfed infants. Both the NIH’s LactMed database and the British Society for Allergy and Clinical Immunology recommend loratadine as a first-choice antihistamine during breastfeeding.
How Much Reaches Your Baby
At doses up to 40 mg (four times the standard 10 mg daily dose), only about 0.03% of the drug is excreted into breast milk over 48 hours. When researchers calculated the relative infant dose, which estimates how much a nursing baby actually receives compared to the mother’s weight-adjusted dose, the figure came in at roughly 1.1%. Anything under 10% is generally considered compatible with breastfeeding, so loratadine falls well below that threshold.
The amount that reaches breast milk is simply too low to cause problems for most babies. Loratadine also has a key advantage over older antihistamines like diphenhydramine (Benadryl): it is far less likely to cross into the brain and cause drowsiness, both in you and in your infant.
Reported Side Effects in Infants
In a survey of 51 breastfeeding mothers taking loratadine, researchers documented two reports of minor sedation in infants and one report of decreased milk production. No other side effects were noted. That’s a reassuringly small number, but it means mild drowsiness is possible in rare cases. If your baby seems unusually sleepy or fussy after you start taking Claritin, that’s worth paying attention to.
Claritin-D Is a Different Story
Standard Claritin contains only loratadine. Claritin-D adds pseudoephedrine, a nasal decongestant, and that ingredient is much more problematic during breastfeeding. In a controlled study, a single dose of pseudoephedrine reduced milk production by an average of 24%, dropping daily output from about 784 mL to 623 mL. That’s a significant decrease, especially for mothers working to maintain supply.
If you’re breastfeeding and need allergy relief, stick with plain Claritin. Check the label carefully, because Claritin-D is often stocked right next to regular Claritin on the pharmacy shelf.
How Loratadine Compares to Other Antihistamines
The NHS Specialist Pharmacy Service and the British Society for Allergy and Clinical Immunology both name loratadine and cetirizine (Zyrtec) as the preferred non-sedating antihistamines during breastfeeding. Either one is a reasonable choice. Cetirizine has a slightly higher chance of causing mild drowsiness in the mother compared to loratadine, but both transfer into breast milk in small amounts and are well studied in nursing populations.
Older, first-generation antihistamines like diphenhydramine (Benadryl) and chlorpheniramine are more likely to sedate both you and your baby. They also carry a greater theoretical risk of reducing milk supply because of stronger effects on certain chemical messengers in the body. For these reasons, the newer options are preferred.
Practical Tips for Taking Claritin While Nursing
Loratadine has an average half-life of about 8 hours in the body, meaning levels gradually decline after you take it. Its active breakdown product sticks around longer, with a half-life of roughly 28 hours, but that metabolite also appears in breast milk at very low concentrations. There’s no strong evidence that timing your dose around feedings makes a meaningful difference given how little transfers overall, but if you want to minimize even that small exposure, taking your dose right after a feeding session gives levels the most time to drop before the next one.
Keep your dose at the standard 10 mg once daily. Higher doses have been studied and still show low milk transfer, but there’s no reason to take more than you need. If standard Claritin isn’t controlling your symptoms, nasal corticosteroid sprays (like fluticasone) are another option that’s compatible with breastfeeding, since they act locally and barely enter the bloodstream at all.
Watch your baby for any unusual sleepiness during the first few days. Most infants show no changes at all, but the small number of sedation reports in the research means it’s worth a quick check. If everything looks normal after the first week, ongoing use at standard doses is not expected to pose a risk.